6-溴-4-碘-喹啉 | 927801-23-8

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-溴-4-碘-喹啉
• 英文名称: 6-bromo-4-iodoquinoline
• CAS: 927801-23-8
• 化学式: C₉H₅BrIN
• 分子量: 333.954
• InChiKey: BWFLFNVNIISPPK-UHFFFAOYSA-N

物化性质

• 沸点：
  375.5±22.0 °C(Predicted)
• 密度：
  2.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-4-iodoquinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-4-iodoquinoline
CAS number: 927801-23-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H5BrIN
Molecular weight: 333.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用6-溴-4-碘-喹啉可用作有机合成中间体和医药中间体，主要应用于实验室研发和化工生产过程。

反应信息

• 作为反应物：
  描述：

  6-溴-4-碘-喹啉 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 芸香苷
  参考文献：
  名称：

  [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers

  摘要：

  GSK2126458 is a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) with low picomolar to subnanomolar activity. [C-11]GSK2126458 and [F-18]GSK212 6458, new potential PET agents for imaging of PI3K and mTOR in cancer, were first designed and synthesized in 40-50% and 20-30% decay corrected radiochemical yield, and 370-740 and 37-222 GBq/lmol specific activity at end of bombardment (EOB), respectively. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.136
• 作为产物：
  描述：

  5-[(4-溴苯基氨基)亚甲基]-2,2-二甲基-1,3-二噁烷-4,6-二酮 在 盐酸 、 丙腈 、 sodium iodide 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醚 、 邻二氯苯 、 甲苯 为溶剂， 反应 104.0h， 生成 6-溴-4-碘-喹啉
  参考文献：
  名称：

  PI3激酶调节剂及其使用方法和用途

  摘要：

  本发明属于药物领域并且具体涉及用于治疗癌症的化合物、组合物及其用途，具体涉及PI3激酶调节剂及其使用方法和用途。本发明提供了一种如式(I)所示的化合物，其药学上可接受的盐，及其药物制剂，用于调节蛋白激酶的活性，并调节细胞间或细胞内的信号响应。本发明同时也涉及包含本发明化合物的药物组合物，并使用该药物组合物治疗哺乳动物，特别是人类高增殖性疾病的方法。式(I)。

  公开号：

  CN103539777B

文献信息

• Identification of 3-amidoquinoline derivatives as PI3K/mTOR dual inhibitors with potential for cancer therapy
  作者：Jiankang Zhang、Xiaodong Ma、Xiaoqing Lv、Ming Li、Yanmei Zhao、Guoqiang Liu、Shuyu Zhan

  DOI：10.1039/c6ra26971k

  日期：——

  A new series of 3-amidoquinoline derivatives were designed, synthesized and evaluated as PI3K/mTOR dual inhibitors.

  一系列新的3-酰胺喹啉衍生物被设计、合成并作为PI3K/mTOR双抑制剂进行评价。
• [EN] PI3 KINASE MODULATORS AND METHODS OF USE<br/>[FR] MODULATEURS DES KINASES PI3 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CALITOR SCIENCES LLC

  公开号：WO2014022128A1

  公开（公告）日：2014-02-06

  This invention relates to the field of lipid kinases and modulators thereof. In particular, the invention relates to modulators of phosphatidylinositol 3-kinases (PI3 kinases or PBKs) signaling pathways, and methods of their use. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in modulating of PI3K signaling pathways and their related disorders in mammals, especially humans.

  该发明涉及脂质激酶及其调节剂领域。具体而言，该发明涉及磷脂鞘氨醇3-激酶（PI3激酶或PBKs）信号通路的调节剂，以及它们的使用方法。该发明还提供了包含这些化合物的药学上可接受的组合物，以及在哺乳动物，特别是人类中调节PI3K信号通路及其相关疾病的使用方法。
• Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor
  作者：Jinsong Han、Ying Chen、Chao Yang、Ting Liu、Mingping Wang、Haojie Xu、Ling Zhang、Canhui Zheng、Yunlong Song、Ju Zhu

  DOI：10.1016/j.ejmech.2016.06.030

  日期：2016.10

  superior pharmacokinetic profiles for animal studies. It significantly inhibited tumor growth when administered orally in an A549 non-small-cell lung carcinoma xenograft and BEL7404 human hepatocellular carcinoma xenograft models. On the basis of its excellent in vivo efficacy and superior pharmacokinetic profiles, 13b has been selected for further preclinical investigation as a promising anticancer drug

  磷酸肌醇3-激酶（PI3K）家族是广泛的人类癌症中最常被激活的酶之一。因此，抑制PI3K代表了一种有前途的癌症治疗策略。在本文中，设计了一系列苄胺取代的芳基磺酰胺类化合物，并使用整合了重点文库设计和虚拟筛选的策略合成了PI3K / mTOR双重抑制剂，从而发现了13b（NSC765844）。化合物13b对PI3Kα，β，γ，δ和mTOR的IC 50分别具有1.3、1.8、1.5、3.8和3.8 nM的强酶抑制作用。通过体外细胞毒性筛选程序在NCI中进一步评估了13b。GI平均的广谱抗肿瘤活性发现针对大约60个人类肿瘤细胞系的50值为18.6nM。图13b显示了用于动物研究的有利的理化性质和优异的药代动力学特征。当在A549非小细胞肺癌异种移植和BEL7404人肝细胞癌异种移植模型中口服给药时，它可以显着抑制肿瘤的生长。基于其出色的体内功效和出色的药代动力学特征，13b已被选作有希望的抗癌药物候选物，用于进一步的临床前研究。
• PI3K/mTOR蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
  申请人：恩瑞生物医药科技（上海）有限公司

  公开号：CN112341434A

  公开（公告）日：2021-02-09

  本发明涉及一种PI3K/mTOR蛋白降解靶向嵌合体(PROTAC)类化合物及其制备方法和医药用途。具体而言，本发明涉及一种通式(I)所示的化合物及其制备方法，以及其作为降解PI3K/mTOR双蛋白激酶的双功能抑制剂的用途，特别是在预防和/或治疗人类疾病包括癌症中的用途。其中，通式(I)中各基团的定义与说明书中的定义相同。
• METHOD OF ADMINISTRATION AND TREATMENT
  申请人：Bachman Kurtis Earl

  公开号：US20130317037A1

  公开（公告）日：2013-11-28

  The present invention provides a method of treating a human with cancer comprising detecting at least one mutation in a PIK3CA gene or at least one mutant protein encoded by said PIK3CA gene from at least one first sample from said human and administering to said human an effective amount of 2,4-difluoro-N-2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide or a pharmaceutically acceptable salt thereof in a pharmaceutical composition if said at least one sample has at least one mutant PI3K protein or a mutation in the PIK3CA gene.

  本发明提供了一种治疗癌症的方法，包括检测来自人体的至少一个第一样本中的PIK3CA基因中的至少一个突变或由该PIK3CA基因编码的至少一个突变蛋白，并且如果该至少一个样本中至少有一个突变PI3K蛋白或PIK3CA基因中的突变，则向该人体施用2,4-二氟-N-2-(甲氧基)-5-[4-(4-吡啶基)-6-喹啉基]-3-吡啶基}苯磺酰胺或其在制药组合物中的药用可接受的盐的有效量。